← Back to Search

Cancer Vaccine

HPV Vaccine Comparison for Human Papillomavirus

Phase 4
Waitlist Available
Led By Anna Wald, MD
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial is comparing two different HPV vaccines to see which is more effective in men and women aged 27-45.

Who is the study for?
This trial is for men and women aged 27-45 in Seattle who haven't had the HPV vaccine and won't get it during the study. They must be able to follow the trial schedule. People with immune issues, cancer treatments, HIV risk without recent negative tests, unstable health conditions like severe hypertension or uncontrolled diabetes, a history of HPV-related cancer, pregnancy or breastfeeding, or allergies to vaccine ingredients can't join.Check my eligibility
What is being tested?
The study compares two fractional doses of different HPV vaccines: bivalent versus nonavalent. Participants' immune responses are checked over two years at specific intervals (baseline, after 4 weeks, then at 6 months, 12 months and finally at 24 months).See study design
What are the potential side effects?
While not specified here, common side effects from HPV vaccines may include pain at injection site, swelling/redness where shot was given; less commonly fever or headache might occur.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HPV antibody detection after fractional HPV vaccination

Trial Design

2Treatment groups
Experimental Treatment
Group I: Nonavalent HPV vaccineExperimental Treatment1 Intervention
One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
Group II: Bivalent HPV vaccineExperimental Treatment1 Intervention
One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HPV vaccine
2013
Completed Phase 4
~3860

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,738 Previous Clinical Trials
1,844,311 Total Patients Enrolled
Anna Wald, MDPrincipal InvestigatorUniversity of Washington
Helen Stankiewicz Karita, MDPrincipal InvestigatorUniversity of Washington
1 Previous Clinical Trials
92 Total Patients Enrolled

Media Library

HPV vaccine (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04235257 — Phase 4
Human Papillomavirus Vaccines Research Study Groups: Nonavalent HPV vaccine, Bivalent HPV vaccine
Human Papillomavirus Vaccines Clinical Trial 2023: HPV vaccine Highlights & Side Effects. Trial Name: NCT04235257 — Phase 4
HPV vaccine (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04235257 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies available for participants of this experiment?

"As per the information available on clinicaltrials.gov, this experiment is presently not recruiting any volunteers. The trial was first published in November 2020 and last updated in March 2022; however, there are 110 other worthwhile studies actively enrolling patients right now."

Answered by AI

Are participants aged 50 or over being accepted for this experiment?

"Patients that wish to be part of this medical trial must fulfill the age requirement of 27-45. For those below 18, there are 25 trials and for patients above 65, 57 clinical trials exist."

Answered by AI

What criteria must be met to participate in this clinical research?

"For this clinical trial, the age range of prospective patients is between 27 and 45 years old. Additionally, all participants must have received HPV vaccinations. The total number of available slots for enrolment stands at 40 individuals."

Answered by AI

What is the risk associated with HPV vaccine administration?

"HPV vaccine has already been approved, so its safety rating is a 3 according to the Power team's assessment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Intradermal, Fractional Dose of HPV Vaccines:
Anna Wald 2020. "Intradermal, Fractional Dose of HPV Vaccines:". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04235257.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top